Predict your next investment

Corporate Venture

See what CB Insights has to offer

Investments

4

Portfolio Exits

2

About Nerveda

Nerveda is a life science seed fund dedicated to advancing pharmaceutical and diagnostic technologies for neurological disorders.

Nerveda Headquarter Location

San Diego, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Nerveda

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Nerveda in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Nerveda News

RetroSense detects $60m acquisition

Sep 7, 2016

7 September 2016 RetroSense detects $60m acquisition Allergan has acquired the Wayne State University spinout, backed by Santen Pharmaceutical and Nerveda, for an upfront payment of $60m with potential milestone payments in future. Author: Thierry Heles, editor RetroSense Therapeutics, a biotechnology spinout of Wayne State University backed by diagnostics company Nerveda, was acquired yesterday by pharmaceutical firm Allergan in an all-cash transaction of $60m. Allergan may further commit regulatory and commercialisation milestone payments for RetroSense's lead candidate, RST-001, a gene therapy targeting degenerative eye disease retinitis pigmentosa. The size of those potential investments has not been disclosed. Founded in 2009, RetroSense is working on gene therapies to restore vision in patients suffering from blindness. The company exploits an approach known as optogenetics, which creates light sensitivity in cells that did not previously have any. The spinout launched a phase 1/2a clinical trial in March 2016 and applied the treatment to patients through to last month. The technology is based on research conducted at Wayne State and Massachusetts General Hospital that was led by Zhuo-Hua Pan, professor at the university's medical school. Pan and his team also collaborated with researchers at Salus University. In November 2015, RetroSense obtained $6m in a series B round 2015 that was backed by pharmaceutical firm Santen Pharmaceutical, BlueWater Angels, RBV Capital and ExSight Capital. Nerveda, BlueWater, SDL Ventures, Tech Coast Angels, and public-private partnership Michigan Economic Development Corporation supported a $6m series A round in January 2015 . Unnamed investors provided $75,000 in seed funding in 2011, according to a securities filing. Brent Saunders, chief executive and president of Allergan, said: "The acquisition of RetroSense and its RST-001 program builds on Allergan's deep commitment to eye care, and our focus on investing in game-changing innovation for retinal conditions, including retinitis pigmentosa, where patients desperately need treatment options. "

Nerveda Investments

4 Investments

Nerveda has made 4 investments. Their latest investment was in RetroSense Therapeutics as part of their Series A on January 1, 2015.

CBI Logo

Nerveda Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/8/2015

Series A

RetroSense Therapeutics

$6M

No

1

6/30/2014

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

12/5/2013

Series C

Subscribe to see more

$99M

Subscribe to see more

10

12/18/2012

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/8/2015

6/30/2014

12/5/2013

12/18/2012

Round

Series A

Seed VC - II

Series C

Series B

Company

RetroSense Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$6M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

Nerveda Portfolio Exits

2 Portfolio Exits

Nerveda has 2 portfolio exits. Their latest portfolio exit was RetroSense Therapeutics on September 06, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/6/2016

Acquired

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

9/6/2016

00/00/0000

Exit

Acquired

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.